Quick Answer
Vor Biopharma Inc. reported Stockholders Equity of -$164.31 million for the year ending 2025.
- Vor Biopharma Inc. showed a decrease of -270.0% in Stockholders Equity from 2024 to 2025.
- This data is from Vor Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$25.12 million | Q2 2020: -$32.99 million | Q3 2020: -$44.14 million | Q1 2021: $267.19 million | Q2 2021: $250.11 million | Q3 2021: $232.96 million | Q1 2022: $194.45 million | Q2 2022: $174.97 million | Q3 2022: $158.73 million | Q1 2023: $230.22 million | Q2 2023: $204.45 million | Q3 2023: $174.78 million | Q1 2024: $123.04 million | Q2 2024: $98.08 million | Q3 2024: $72.96 million | Q1 2025: $66.07 million | Q2 2025: -$1.51 billion | Q3 2025: -$2.23 billion.
- Over the full 7 years of available data (2019 to 2025), Vor Biopharma Inc.'s Stockholders Equity has declined by 842.8%.
- Historical annual values: Fiscal year 2025: -$164.31 million | Fiscal year 2024: $96.66 million | Fiscal year 2023: $150.72 million | Fiscal year 2022: $250.61 million | Fiscal year 2021: $216.26 million | Fiscal year 2020: -$59.07 million | Fiscal year 2019: -$17.43 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: